Bioatla (BCAB) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Mar, 2026Executive summary
Special meeting of stockholders scheduled for March 4, 2026, will be adjourned and reconvened virtually on March 23, 2026, to vote on key proposals.
Main agenda includes approval of a merger between the company and its wholly owned subsidiary, BA Merger Sub, Inc.
Amendment No. 1 to the Merger Agreement ensures the company's certificate of incorporation remains unchanged post-merger.
Board of Directors unanimously recommends voting in favor of both the Merger Proposal and the Adjournment Proposal.
Only stockholders of record as of February 2, 2026, are entitled to vote at the meeting.
Voting matters and shareholder proposals
Stockholders will vote on the Merger Proposal and the Adjournment Proposal.
Approval of the Merger Proposal requires a majority of outstanding shares.
Proposals are now considered routine, allowing brokers to vote shares held in street name without owner instructions.
Proxies previously submitted will be voted as instructed unless revoked or changed before the meeting.
Voting can be done by proxy card, phone, internet, or electronically during the meeting.
Board of directors and corporate governance
The Board of Directors approved Amendment No. 1 to the Merger Agreement.
Board continues to recommend voting “FOR” both proposals.
Jay M. Short, Ph.D., serves as CEO and Chairman of the Board.
Latest events from Bioatla
- Q1 2025 saw narrowed losses, strong clinical data, and a cash runway into 1H 2026 amid funding risks.BCAB
Q1 20259 Jul 2026 - FDA-aligned Phase 3 trial, milestone payment, and low cash highlight progress and risk.BCAB
Q3 202530 Jun 2026 - Q3 2024 featured clinical progress, reduced losses, and a licensing deal extending cash runway to 2026.BCAB
Q3 202430 Jun 2026 - Annual Meeting to vote on directors, auditor, and executive pay, with virtual participation options.BCAB
Proxy filing3 Jun 2026 - Shareholders will vote on director elections, auditor ratification, and executive pay, all recommended for approval.BCAB
Proxy filing3 Jun 2026 - Net loss narrowed, cash remains low, and strategic review continues amid going concern risks.BCAB
Q1 202615 May 2026 - CAB platform delivers tumor-selective therapies with strong efficacy and safety in solid tumors.BCAB
Investor presentation31 Mar 2026 - Net loss of $59.6M in 2025, cash runway through H1 2026, and a 70% workforce reduction amid strategic review.BCAB
Q4 202531 Mar 2026 - Shareholders to vote on a 1-for-50 share consolidation to address Nasdaq listing compliance.BCAB
Proxy Filing11 Feb 2026